Date: 2012-07-02
Type of information: Grant
Company: Medicyte (Germany)
Investors:
Amount: €4.2 million
Funding type: grant
Planned used: The grant will support the Re-Liver project that aims to design a biomimetic bioartificial liver.
Others: Medicyte, a german company specialised in the controlled generation and standardisation of human primary cell products for cell therapy and cell-based R&D, has announced that Medicyte, The Electrospinning Company (UK) and the Universities of Manchester (UK) and Pisa (Italy) launch a European wide unique project with the aim to design a biomimetic bioartificial liver (Re-Liver). The company GABO:mi ensures professional project management.
The aim of Re-Liver is to reconstitute a standardized and reproducible bioartificial liver organoid (BLO) using healthy human liver as an architectural and biomaterial template. According to the EMA criteria, the BLO is a cell-based medicinal product, a highly innovative and complex medicine. In addition to the Advanced Therapy Medicinal Product (ATMP), new diagnostic tools and further products in cell-based applications will be developed and validated by the Re-Liver Consortium, made up of three industrial partners, all SMEs, focusing the commercialisation of market-leading products across Europe and further afield. The results of Re-Liver could be used for minimal invasive implantation to treat metabolic diseases, such as Haemophilia A, minimizing the transition from concept to clinic, and finally as an alternative for solid organ transplantation - giving new hope to over 10,000 people waiting for a liver transplant in the EU.
Therapeutic area: Regenerative medicine - Liver diseases
